Pharmacological inhibition of uncontrolled cell growth with small molecule inhibitors is a potential strategy against glioblastoma multiforme (GBM), the most malignant primary brain cancer. Phenotypic profiling of the neurogenic small molecule KHS101 revealed the chemical induction of lethal cellular degradation in molecularly-diverse GBM cells, independent of their tumor subtype, whereas non-cancerous brain cells remained viable.
Introduction
GBM is the most common malignant primary brain tumor in adults and among the most devastating cancers (1) . Its overall median time to recurrence after surgery and standard chemoradiotherapy is ~7 months and the 5-year survival rate remains low (<5%) (2) . As examples of the potential therapeutic promise shown by small molecules, pre-clinical data support anti-GBM effects through perturbation of cell death programs (3), transcriptional and epigenetic pathways (4, 5) , lethal autophagy (6) , and GBM stem cell self-renewal (7) . However, GBM biology remains poorly understood and there is an unmet need for the identification of molecular GBM vulnerabilities and the development of pharmacological strategies to exploit them (2) . In addition, to yield potential novel drug candidates, phenotypic drug discovery and profiling approaches can address the complexity of diseases, in particular, when the molecular target(s) and MOA that underlie a small molecule effect are identified (8, 9) .
Here, we hypothesized that an experimental small molecule could identify molecular vulnerabilities in patient-derived GBM cells that possess stem cell-like characteristics (10) . Our investigation focused on the 4-aminothiazole derivative KHS101 as it penetrates the blood brain barrier (BBB) and promotes neural progenitor cell differentiation at the expense of proliferation in the adult rat (11) . As inter-and intratumor heterogeneity is a major impediment to broadly efficacious GBM therapy, we sought to address whether KHS101 can affect a spectrum of clinically-relevant GBM subtype(s). To achieve this, we established a panel of different patient-derived primary and recurrent GBM cell models that were characterized through cytogenetic and single cell gene expression analysis. We observed that KHS101 leads to a rapid and selective cytotoxic response in this heterogeneous spectrum of patient-derived GBM cell models. Accordingly, we sought to identify the MOA behind the KHS101 anti-GBM activity utilizing affinity-based target identification, orthogonal chemical validation, and detailed analysis of energy metabolism and mitochondrial proteostasis. Furthermore, we investigated the compound's anti-GBM activity in established xenograft tumors upon systemic administration.
Results

KHS101 selectively induces GBM cell cytotoxicity independent of molecular subtypes
GBM is characterized by intra-and intertumor heterogeneity that may hinder therapeutic success (12) (13) (14) . To represent this molecular heterogeneity, we established six patient-derived tumor cell models from primary GBM (GBM1, 4, 13), recurrent GBM (GBM20), and rare GBM subtypes such as gliosarcoma (GBM11) and recurrent giant cell GBM (GBM14, 'stemness', cell cycle, and GBM subtype classifier genes, computational analysis revealed that our GBM models contain heterogeneous cell populations with single (mesenchymal or proneural) or double (classical/proneural, mesenchymal/proneural) subtype signatures (Fig. 1B and C, Supplementary Report 1). Independent of clinical and molecular subtype features (including classical, proneural, and mesenchymal subtype compartments, primary versus recurrent tumor origin, and MGMT hypo-and hypermethylation), KHS101 attenuated cell growth and survival in several different GBM cell models but had no discernible effect on noncancerous adult brain progenitor (NP) cells (whose derivation is described in (10) ; Fig. 1D ).
Dose response curves further indicated selective cytotoxicity of KHS101 against all GBM cell models as well as GBM cell lines U251 and U87, while two different NP lines (NP1 and NP2)
were refractory (Fig. 1E, Supplementary Fig. 1 ). Consistent with a KHS101-induced proapoptotic cell fate, a marked increase in caspase 3/7 activation, increased expression of the harakiri activator of apoptosis (HRK), and accumulation of Annexin V-positive apoptotic cells was observed 48 hours after KHS101 addition (Fig. 1F , G, and H). Electron microscopy (EM) imaging performed 12 hours after KHS101 addition revealed that GBM apoptosis was preceded by the pronounced development of intracellular vacuoles and degradation of electron-dense cytoplasmic content in GBM compared with NP cells ( Fig. 2A and B, Supplementary Fig. 2 ). Concomitantly, we observed an increase in the LC3B-positive autophagosomal compartment in all GBM but not NP cell models (Fig. 2C, D , and E). Neither bone morphogenetic protein 4 (BMP4)-induced differentiation of GBM cells (15) nor reduced oxygen tension (5% O2) (16) modulated KHS101 cytotoxicity ( Fig. 2F and G) . Taken together, these findings indicate a selective induction of GBM cell cytotoxicity by a single agent in a spectrum of disease-relevant cellular contexts.
KHS101 binds mitochondrial HSPD1 in GBM cells
TACC3 is a relevant target of KHS101 in rodent neural progenitor cells (11) , and KHS101 has been shown to cause cellular destabilization of TACC3 (17) . Consistently, Western blot analysis showed that KHS101 reduced TACC3 levels from ~18 hours onwards in the GBM1 model (comparable to TACC3 knockdown, Supplementary Fig. 3A and B) . However, a rapidlyincreasing autophagic response was observed in the KHS101-treated GBM cells before the levels of TACC3 were reduced by the compound (Fig. 3A) . Moreover, the cytotoxic KHS101 phenotype was not recapitulated by TACC3 knockdown, hence excluding TACC3 downregulation as the relevant MOA ( Supplementary Fig. 3C ). Microarray transcriptome profiling (ArrayExpress, accession E-MTAB-5713) and gene set enrichment analysis (GSEA) of GBM1 cells in the presence of KHS101 suggested that, in addition to the cell cycle, oxidative phosphorylation (OXPHOS) and the tricarboxylic acid (TCA) cycle were significantly altered by KHS101 (Fig. 3B) . Consistently, extracellular flux analysis (protocols described in (18) ) revealed an acute decline in basal oxygen consumption rates (OCR; ~40%) and mitochondrial oxidative capacity (by ≥70%) in GBM1 cells (Fig. 3C ).
Dysregulated mitochondrial processes are important mediators of tumorigenesis (19) .
To elucidate the cellular target(s) underlying the reduced mitochondrial capacity in KHS101-treated GBM cells, we investigated the physical interaction of KHS101 with potential cellular protein(s) using an established affinity-based target identification protocol (11) . The photoaffinity probe KHS101-BP (a KHS101 derivative containing a benzophenone moiety and an alkyne substituent) and KHS101 showed similar bioactivity in GBM cells (Fig. 3D , Supplementary Fig. 4A and B). A distinct KHS101-BP-protein complex of ~60 kDa (pI~5.7), that was competed away with a 50-fold excess of free KHS101, was identified (Fig. 3E ). Proteomics analysis revealed that KHS101-BP-bound protein corresponded to the mitochondrial 60 kDa heat shock protein 1 (HSPD1). KHS101-HSPD1 binding was confirmed in pull-down and thermal shift experiments in vitro using human recombinant HSPD1 protein ( Fig. 3F and Supplementary Fig. 4C ). Cellular fractionation followed by Western blotting showed that HSPD1 was overexpressed in GBM cells and predominantly localized to the mitochondria (Fig.   3G ). Consistent with a reported role for HSPD1 in proliferation and complex I integrity in the glioma cell line U87 (20) , we found that stable HSPD1 knockdown led to a decline in both proliferation and mitochondrial oxidative capacity in GBM1 cells, suggesting an increased dependency on HSPD1 expression and function ( Supplementary Fig. 5 ). However, KHS101 altered neither HSPD1 expression nor HSPD1 protein levels (Fig. 3G) , hence excluding knockdown kinetics as a biologically relevant mechanism underlying the KHS101-GBM cytotoxicity.
KHS101 selectively aggregates HSPD1 and metabolic enzymes in GBM cells promoting their metabolic exhaustion
To investigate whether the KHS101-HSPD1 interaction inhibits HSPD1 enzymatic function, we assessed HSPD1 chaperone activity in vitro upon KHS101 addition. KHS101 elicited a concentration-dependent inhibition of substrate re-folding (Fig. 4A) . Furthermore, the GBM cell degradation phenotype and OXPHOS reduction elicited by KHS101 was recapitulated by the mitochondrial HSPD1-binding natural product myrtucommulone (MC (21); Fig. 4B and Supplementary Fig. 6 ). As these data further confirmed the HSPD1-targeting properties of KHS101, we quantified protein aggregation by fractionation of detergentinsoluble mitochondrial proteins in GBM compared with NP control cells. Silver staining indicated that aggregated proteins were selectively enriched in GBM1 compared with NP1 cells 1 hour after KHS101 addition (Fig. 4C) . Proteomics analysis identified HSPD1 as well as enzymes with functions in glycolysis (e.g., ALDOA), TCA cycle (e.g. DLST), oxidative phosphorylation (OXPHOS; e.g. ATP5A1), and mitochondrial integrity (e.g., LONP1 (22) ) in the aggregated fractions specifically in the KHS101-treated GBM cells (Supplementary Table 1 ).
These proteins readily integrated into a predicted functional protein-protein interaction network (Fig. 4D) . Consistent with the dysfunction of GBM cell metabolism-regulating enzymes, qRT-PCR analysis of 25 key genes altered in the GBM1 transcriptome analysis (ArrayExpress, accession E-MTAB-5713) displayed a KHS101-induced signature of glycolytic/ oxidative/autophagic stress accompanied by loss of known GBM 'stemness' markers (e.g., NOS2 (23), ID1 (24) , and OLIG2 (25)) in KHS101-treated GBM versus NP cells (Fig. 4E) .
Furthermore, to confirm reduced HSPD1 function by KHS101 in vivo, we examined expression of DDIT3 (alias CHOP), a key marker of the unfolded mitochondrial protein response in glioma cells (26) . Consistent with an increase of DDIT3 expression in GBM cell culture (Fig. 4E ), KHS101 induced a marked upregulation of DDIT3 protein levels in the GBM1 xenograft model (10) (Fig. 4F) . In agreement with a causative relationship between chemical HSPD1 inhibition and bioenergetic failure in GBM cells, stable isotope substrate labeling with U-13 C glucose (27) revealed that both glycolytic and TCA flux were selectively impaired in GBM1 cells 4 hours after KHS101 addition. Increased 13 C enrichment of intracellular glucose was concomitant with decreased 13 C incorporation into the glycolytic end-product lactate (Fig.   5 ). Moreover, the incorporation of the 13 C-label into TCA cycle intermediates citrate and succinate markedly decreased in KHS101-treated GBM compared to NP cells (Fig. 5 ). This bioenergetic flux deficiency was accompanied by mitochondrial degradation (assessed by Immuno-EM 8 hours after KHS101 treatment; Supplementary Fig. 7A ), and a reduction in GBM cell mitochondrial mass that was not evident in the NP control cells (assessed by silver staining 4 hours after KHS101 treatment; Supplementary Fig. 7B ). Consistently, cellular ATP levels were markedly depleted in GBM1 compared to NP1 cells ( Supplementary Fig. 7C ).
KHS101 attenuates tumor proliferation and invasion in vivo
It has been shown that the mitochondrial unfolded protein response can be exploited for anti-glioma therapy (26) . Accordingly, we investigated the pharmacological effects of KHS101 in vivo using xenograft tumors that were allowed to establish for 6 weeks after injection of GBM1 cells (1 x 10 5 ) into the forebrain striatum. We adapted the KHS101 dosing regimen from previous neurogenesis work in rats (11) Compared with normal brain, gliomagenesis is associated with elevated HSPD1 expression that negatively correlates with patient survival (Fig. 7A, Supplementary Fig. 8C ).
Accordingly, we further investigated whether KHS101 prolonged survival in a suitable xenograft model (characterized by a predictable onset of morbidity). To this end, we used a different (giant cell GBM-based) model, established with exclusively in vivo-propagated primary cells (GBMX1; onset of morbidity: 10-13 weeks). In two independent experiments (using early removal criteria within a moderate severity bandwidth), we found that the survival of animals carrying GBMX1-tumors (established 2 or 6 weeks before treatment) was markedly increased using the aforementioned treatment regimen for 10 weeks (Fig 7B) , or continuously until the experimental endpoints (Fig. 7C) . Histological endpoint analysis of KHS101-and vehicle-treated animals confirmed a significantly decreased tumor burden (~2-fold) in the animals that had received continuous KHS101 treatment (Fig. 7D ). In summary, these results indicate significant anti-GBM effects of KHS101 in vivo, without discernible adverse toxicity.
Discussion
GBM is a devastating cancer with limited treatment options and correspondingly poor patient outcomes. We based our investigation on the hypothesis that a synthetic small molecule can significantly suppress GBM tumor progression and focused on the compound KHS101 that shows BBB penetrability as well as non-toxic neuronal differentiation properties in vitro and in vivo (11) . One challenge for GBM target discovery and validation is to incorporate the ever-changing composition of molecularly and phenotypically diverse tumor cell populations (12, 13) into preclinical disease modelling. However, transcriptional diversity among and within our six patient-derived models was revealed by microfluidic single cell qRT-PCR analysis. We developed computational approaches that robustly indicated classical, proneural, and mesenchymal GBM subtype compartments in our GBM models (Supplementary Report 1). Notably, KHS101 cytotoxicity was independent of GBM subtype features, parental tumor origin (primary versus recurrent GBM), and MGMT methylation status ( Fig. 1) . Neither pro-differentiation signaling (10, 15) nor low oxygen culture conditions (that can promote GBM clonogenicity (28)) significantly changed the GBM cell sensitivity to KHS101. Overall, these results point towards a molecular mechanism that is distinct from 'forced' GBM stem cell-like differentiation (a non-cytotoxic phenotype that develops over several days (10) ). Consistently, the KHS101-mediated downregulation of the neural stem cellpromoting factor TACC3 over 48 hours was not involved in the immediate metabolic response characterized by mitochondrial dysfunction and bioenergetic deficiency in GBM compared with NP cells.
In agreement with KHS101-induced mitochondrial stress, affinity-based target identification revealed a physical interaction between KHS101 and the mitochondrial chaperone HSPD1 (Fig. 2 ). In line with this finding, KHS101 rapidly inhibited enzymatic HSPD1 activity without affecting the chaperone's protein or gene expression levels. These results highlight the significance of recognizing and exploiting differences between genetic and smallmolecule target inhibition (e.g., reviewed in (29, 30) ). Accordingly, the HSPD1-targeting properties of KHS101 were further strengthened by an independent chemical positive control (MC) that recapitulated the KHS101-induced GBM cell degradation phenotype. Intriguingly, MC (a non-prenylated acylphloroglucinol) and KHS101 (a thiazole derivative) share anti-cancer and mitochondrial HSPD1-targeting properties (21, 31) , and it is unlikely that these chemicallydistinct entities phenocopy each other due to 'off-target' effects (29) . In agreement with the observed concentration-dependent inhibition of HSPD1 chaperone activity by KHS101, we detected a significant selective aggregation of mitochondrial proteins in GBM cells 1 hour after KHS101 addition. The attenuation of activities facilitated by enzymes such as ALDOA (regulating glycolysis), DLST (regulating TCA cycle), SLC25A3 and ATP5A1 (regulating OXPHOS), and the chaperone LONP1 (regulating mitochondrial integrity in cancer cells) were consistent with the wide-ranging metabolic stress observed in the GBM but not NP cells (Fig. 3) . In addition, this GBM mitochondrial unfolded protein response was in line with the observed KHS101-induced upregulation of DDIT3 (alias CHOP) expression in vivo, corroborating evidence for a link between mitochondrial homeostasis and GBM cellular fitness (26, 32) .
Importantly, selective effects of KHS101 towards brain cancer cells were observed throughout our study at protein, metabolite, mRNA, and organelle level. In agreement with these findings, KHS101 is not toxic in other non-cancer contexts (11, 17) . For example, previous studies afforded to KHS101 showed favorable in vivo properties including accelerated neuronal differentiation in adult rats (without affecting apoptosis of brain cells; (11)). Consistent with the specific KHS101 cytotoxicity in GBM compared with NP cells, the compound markedly decreased the progression of established xenograft tumors and adverse effects (e.g., liver toxicity) were not observed in treated mice after prolonged (10-week) administration (Fig. 4) .
In summary, this experimental small molecule phenotype and target profiling study identifies HSPD1 enzymatic function as a specific molecular vulnerability in GBM cells. The data indicate that a lethal GBM cell fate can be selectively triggered in a heterogeneous spectrum of GBM cells by a single agent. The cytotoxic activity of KHS101 was selective for tumor cells highlighting a dependency on mitochondrial HSPD1 chaperone activity that critically facilitates GBM cell energy metabolism. These findings may be exploited for therapeutic development(s), and future studies are warranted to address the role of HSPD1 in the metabolic reprogramming driving brain tumorigenesis.
Methods
Patient-derived GBM cell models
Adherent culture of the GBM1, GBM4, and the NP cell models has been previously described (14) . Additonal models were derived under the governance of the ethicallyapproved Leeds Multi-disciplinary Research Tissue Bank using similar methodology. U-87 MG (ECACC, 89081402) and U251 cells were cultured in DMEM medium supplemented with 10% (v/v) fetal bovine serum. All cell lines were confirmed as mycoplasma negative.
Single cell isolation and profiling
Individual GBM cells were captured from cell suspensions using the microfluidic Fluidigm C1 single-cell auto prep system (Fluidigm). Reverse transcription and preamplification were carried out within a 96-well microfluidic C1 chip according to the manufacturer's instructions using DELTAgene assays (Fluidigm, Supplementary Table 2) . Table 2 ). Amplified cDNA (3.3 μL) was mixed with 2x Ssofast EvaGreen Supermix (2.5 μL), Low ROX buffer (2.5 µL; Bio-Rad, PN 172-5211, Hercules, CA, USA), and 'sample loading agent' (0.25 μL; Fluidigm, PN 100-3738).
DELTAgene forward and reverse primers were mixed with Fluidigm Assay Loading Reagent (2.5 μL). Samples and assays were loaded onto Fluidigm M96 chips using the HX IFC Controller (Fluidigm) and then transferred to the BioMark™ HD real-time PCR reader following the manufacturer's instructions. PCR was performed using the (GE Fast 96 × 96 PCR + Melt v2.pcl) thermal protocol: Thermal Mix of 70°C, 40 minutes; 60°C, 30 seconds, Hot Start at 95°C, 1 minute, 30 cycles of (96°C, 5 seconds; 60°C, 20 seconds), and 'Melting' using a ramp from 60°C to 95°C at 1°C/3 seconds. Data were analyzed using the Fluidigm Real-Time PCR Analysis software and Ct and melting-curve data were exported to Excel and R for further analysis.
Results were assessed using the Fluidigm Real-Time PCR Analysis software (heat map view).
Melting curve analyses was carried out to identify non-specific amplicons, which were removed from the final data set. For calculation of relative expression values (∆Ct = LoD CtCt), the limit of detection (LoD) was set to a Ct value of 30 (Ct values of '999' were allocated artificial values ≥30 to allow for the visualization of 'non-expressors' in bean plots). Plots were generated using BoxPlotR (33)
Computational single cell gene expression analysis
After transformation of Ct to expression values, missing values (e.g., resulting from unspecific amplicons removed after melting curve analysis) were imputed using k-nearest neighbor imputation (34) . Single-cell expression levels were adjusted for cell cycle-dependent heterogeneity as described in (35) using 20 known cell cycle markers. Gene expression levels of tumor samples with subtype annotation were obtained from (14) and integrated with our single cell qPCR data set. To this end, both data sets were separately discretized to three levels on a per gene basis using mixture models. Subsequently, a Random Forest classifier was trained on the data set reported by Verhaak and colleagues (14) , and used to predict the 
Electron Microscopy
For standard EM cell pellets were fixed in 4% (w/v) formaldehyde/glutaraldehyde solution in 100 mM phosphate buffer at room temperature (RT) for 30 minutes, and subsequently washed (2 x 10 minutes) and stored at 4°C in 100 mM phosphate buffer. Cells were then post-fixed with 1% buffered osmium tetroxide on ice for 45 minutes, washed in 100 mM phosphate buffer (2 x 10 minutes) then treated with buffered 1% tannic acid solution (10 minutes) and washed again (100 mM phosphate buffer; 2 x 10 minutes). Cell samples were stained with 2% uranyl acetate and dehydrated in increasing concentrations of ethanol/acetone before embedding. These samples were then polymerized overnight at 70°C.
Processed cell pellets were sectioned to 1 µm on a Leica EM UC7 microtome and stained with toluidine blue. Further thin sections were then taken (70 nm) and placed on 300 mesh uncoated copper grids, and these were stained with saturated uranyl acetate in 50% ethanol 
Cytogenetic analysis of tumor cells
GBM cells and NP1 cells were analyzed for alterations in chromosomes 7 and 10 using fluorescence in-situ hybridization (FISH) methodologies for EGFR and PTEN respectively. Cells were grown to 50% confluency and then exposed to 0.2 mg/ml colcemid for four hours at 37°C. Subsequently, cells were collected following 3 minutes exposure to trypsin/EDTA (Gibco; 15400054). Resultant cell suspensions were harvested using 15 minutes exposure to a 50:50 mixture of pre-warmed 0.075 M KCl/1% Sodium Citrate, followed by 3 washes in Carnoy's fixative. Slides previously stored in absolute ethanol were used to make preparations from the fixed cell suspensions (60°C for 30 minutes). EGFR FISH studies were carried out using the directly labelled Kreatech EGFR (7p11) / SE7 probe. PTEN FISH studies were carried out using the Vysis PTEN / CEP10 FISH Probe Kit according to manufacturer's instructions. Interphase cells (~100) were analyzed by epifluorescence microscopy for signal imbalance. Deletions were called when seen in over 20% of cells. Amplification was defined as over four times the copy number for a given cell ploidy.
Chemical synthesis
All chemical reagents for synthesis were purchased from commercial suppliers and used without further purification. When used as reaction solvents, THF and DCM were dried and deoxygenated using an Innovative Technology Inc. PureSolv® solvent purification system. The synthesis of KHS10, KHS101-BP, and KHS101-biotin is described in the Supplementary Information.
Cellular assays
For live cell analysis, cells were allowed to grow for 2 days before the addition of KHS101 (7.5 µM) or DMSO (0.1%), and subsequently monitored for 3 days. Images were acquired at 45 minute intervals using the IncuCyte ZOOM® live cell imaging system (Essen Bioscience). Cellular growth rates per hour (GR, %) were calculated for a 60 hour period: GR = [78-hour-confluency (%) -18-hour-confluency (%)] / [18-hour-confluency (%) x 60 hours].
Confluency curves were based on relative values (normalized to the to time point).
For the analysis of cell viability and caspase 3/7 activation, cells were seeded into 96 well plates (Greiner bio-one; 655073) at densities of 10,000 and 2,500 cells, respectively. The following day, cells were treated with vehicle (DMSO) or KHS101 (1-20 µM) in 100 µL of medium and the CellTiter-Glo® and Caspase-Glo® 3/7 assays (Promega) were carried out at the indicated time points according to the manufacturer's instructions.
For the quantification of apoptosis using annexin V and propidium iodide, GBM1 cells were treated with KHS101 (7.5 µM) or vehicle (DMSO, 0.1%) for 48 hours, then harvested with trypsin, washed with PBS, and stained with Annexin V and Propidium Iodide for 15 minutes at 37 0 C using an Annexin V-fluorescein staining kit (Roche) in accordance with the manufacturer's protocol. Labelled early apoptotic and late apoptotic/necrotic cells were quantified through quadrant gating using a NC3000 cytometer (Chemometec).
Autophagic kinetics were assessed using the CytoID ® detection assay (Enzo Life Sciences) according to the manufacturer's instructions (1:500 dilution). Stained live cells were imaged using an EVOS digital inverted fluorescence microscope.
For the differentiation assay, cells were seeded into 96 well plates (Greiner bio-one; 655073) at a density of 5,000 cells per well and treated with recombinant human BMP4 at 100 ng/mL for 4 days. Subsequently, cells were treated for 48 hours with DMSO (0.1%) or KHS101
(1-20 µM) in 100 µL of medium and the CellTiter-Glo® assay (Promega) was carried out according to the manufacturer's instructions.
For the colony formation assay, cells were seeded at a density of 125 cells/well in 24-well plates and allowed to adhere. The following day, the single cells per well were counted and treated with DMSO or KHS101. Colonies consisting of >6 cells were counted after 10 days and the percentage of cells that were able to form a colony was determined.
Gene Expression analysis
Gene expression profiling was carried out using the Illumina HumanHT-12 v4 beadchip.
Raw data were pre-processed with a quantile normalization method using Bioconductor.
Differential analysis log fold changes were calculated for all probes and those with a false discovery rate (FDR) ≤ 0.075 were selected.
For qRT-PCR analysis, total RNA was extracted using the RNeasy mini kit (Qiagen) according to the manufacturer's instructions. Copy DNA was synthesized using the SuperScript II first-strand-synthesis method with oligo(dT)s (Invitrogen) and analyzed using TaqMan® gene expression assays (Supplementary Table 3 ). High-throughput qRT-PCR was carried out using the Fluidigm BioMark™ HD System. Data were internally normalized to Glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Images were acquired using an EVOS digital inverted fluorescence microscope (life technologies) or a Nikon A1R confocal microscope.
Immunocytochemistry
TACC3 and HSPD1 lentiviral-based RNAi
Generation of lentiviral particles was carried out according to the manufacturer's specifications and as previously described (10 
Western blotting
Complete cellular extracts (~10 6 cells) were lysed in CellLyticMT (Sigma; C3228) plus protease/phosphatase inhibitor cocktail (Thermo Scientific; 78440) following the manufacturer's recommendations. To achieve nuclear/cytoplasmic separation of total cellular protein, the CelLytic ™ NuCLEAR ™ Extraction Kit (Sigma; NXTRACT-1KT) was used. For mitochondrial/cytosolic fractionation the Mitochondria Isolation Kit for Cultured Cells (Thermo Scientific; 89874) was utilized. Lysate concentrations were determined using the BCA protein assay (Pierce; 23225). Protein (between 15-30 μg) was loaded onto Mini-Protean TGXTM pre-cast gels (10%; Biorad), and transferred onto a nitrocellulose membrane (0.45 µm, Biorad). Membranes were exposed to the following antibodies: mouse anti-TACC3 (Santa Cruz; sc-48368; 1:500), mouse anti-Actin beta (Sigma; A5441; 1:20,000), rabbit anti-COX IV (Cell Signaling; 4850; 1:500), rabbit anti-Hsp60 (Abcam; ab46798; 1:500) combined with secondary anti-rabbit (Thermo; G-21234; 1:2000) or anti-mouse (Sigma; A4416; 1:5000) antibodies conjugated to horseradish peroxidase. Membranes were developed using the Luminata Crescendo or Forte Western HRP substrate solutions (Millipore).
Quantification of metabolic phenotypes
Metabolic analysis in real-time was carried out using the XFp extracellular flux analyser (Seahorse Bioscience). Changes to mitochondrial function or glycolytic flux where assessed with 'Mito Stress Test' or 'Glycolysis Stress Test' kit protocols (Seahorse Bioscience 101848-400 and 103020-400) using seeding densities of ~30,000 cells per well. Prior to analysis, the culture medium was replaced with XF base media (Agilent; 102353-100) and the cells transferred to a 37°C non-CO2 humidified incubator. For the 'Mito Stress Test' XF base media was supplemented with glucose (25 mM; Sigma; G8769) and sodium pyruvate (0.5 mM; Sigma; S8636). L-glutamine (2 mM; Gibco; 35050-061) was used for both 'Mito and Glycolysis Stress Tests' with NP cells. Supplemented culture media were adjusted to pH 7.4 and filtered through a 0.2 µm filter, and maintained at 37°C throughout the experiments. KHS101 and vehicle (DMSO) were injected at the indicated concentrations after the baseline metabolic flux readings were established. Oligomycin (1 µM), FCCP (0.5 µM), antimycin and rotenone (0.5 µM) were injected according to the 'Mito Stress Test' protocol. Glucose (10 mM), oligomycin (1 µM) and 2-deoxy-glucose (100 mM) were sequentially injected according to 'Glycolysis Stress Test' protocols.
Gas Chromatography-Mass Spectrometry stable isotope flux analysis of methoximation and silylation-derivatized metabolites was carried out as previously described (27) . Metabolites were extracted from NP1 and GBM1 cells following a 4 hour treatment with KHS101 (7.5 μM) or DMSO (0.1%) in media containing U-13 C glucose.
Cellular ATP was determined 24 hours after treatments with KHS101 using a luminescence-based readout as described above (CellTiter-Glo® assay; Promega). Data were normalized to DMSO controls.
Thermal stability analysis
The NanoTemper Technologies' Prometheus NT.48 instrument was used for studying the compound's effect on HSPD1 thermal stability. KHS101 or vehicle (DMSO) was added to 30 µl of a 1 mg/mL HSPD1 solution at the indicated concentrations. The thermal stability of HSPD1 was observed in a 1°C/min thermal ramp from 20°C to 95°C with an excitation power of 75%. The emission wavelengths of tryptophan fluorescence at 330 nm and 350 nm were measured. Tm values were calculated from first derivative automatically using the PR.Control software.
Histology and immunohistochemistry
After fixation with 4% (w/v) PFA at 4°C for two days, brains were placed in a sucrose solution (25% sucrose in 0.5 M NaH2PO4, 0.5 M Na2HPO4) until they had sunken to the bottom of the tube. Subsequently, the brains were snap frozen and cut as 30 µm sections on a cryostat. The sections were stored at -20°C in Walter's antifreeze solution (13 mM NaH2PO4, 55 mM Na2HPO4, 30% (v/v) ethyleneglycol, 30% (v/v) glycerol). Prior to staining, the sections were equilibrated in PBS for 10 minutes. Sections were either stained with Hematoxylin and Eosin using standard protocols or subjected to immunohistochemical staining. minutes. Cells were lysed using 0.5% Triton X-100 and protease inhibitor cocktail (Sigma, cat # P8340). Cell lysates were incubated with 25 μM biotin azide (ThermoFisher, cat # B10184), 1 mM TCEP, 100 mM ligand (TBTA), and 1 mM aqueous copper sulfate at 4°C overnight.
Subsequently, proteins were fractionated using ammonium sulfate and the 20-40% fractions were subject to 2D SDS/PAGE. Biotin-labeled proteins were detected through Western blotting using Abcam ab1227). Protein spots corresponding to the specific biotin-labeled proteins were visualized with silver staining on parallel gels. A distinct spot was excised and protein identified using liquid chromatography tandem mass spectrometry.
Human HSPD1 and KHS101 in vitro binding
A total of 1 μg recombinant HSPD1 (Abcam; ab113192) was diluted in 1 mL PBS (with 2mM MgCl2, 2 mM DDT, and 0.1% tween 20) and incubated with 5 μM biotinylated KHS101 at 4°C overnight in the presence or the absence of non-labelled KHS101. Streptavidin agarose beads were added to the incubation mixture and rotated at 4°C for 2 hours. The beads were then precipitated and washed three times in PBS. Bound proteins were eluted with 2x SDS sample buffer and analyzed with SDS/PAGE followed by silver staining and Western blotting.
HSPD1 protein refolding assay
The effect of KHS101 on HSPD1 mediated protein folding was assessed using the human HSP60/HSP10 protein refolding kit (R&D Systems, Cat # K-300) following the manufacturer's instructions (no unspecific effect of KHS101 on the luminescence signal of client protein in absence of heat-induced protein denaturation was observed).
Mitochondrial protein fractionation
Mitochondrial organelles were isolated from 10 7 cells treated for 1 hour with DMSO (0.1%) or KHS101 (7.5 µM) using the Thermo Scientific Mitochondrial Isolation Kit (#89874).
Mitochondrial preparations were normalized to the protein content and detergent soluble and insoluble fractions were separated by NP40 (v/v) treatment at indicated concentrations.
Incubation was on ice for 20 min, and centrifugation at 12000 x g for 20 minutes at 4°C.
Supernatant and pellet were separated and analysed by SDS-PAGE electrophoresis and silver staining.
Xenograft tumor experiments
Animal experiments were carried out under UK project license approval and institutional guidelines. Animals were maintained under standard conditions (12 hour day/night cycle with food and water ad libitum). Experiments were carried out using 6 to 8-week-old NOD scid gamma (NSG) and BALB/c Nude mice for the GBM1 and GBMX1 models, respectively. Mice were stereotactically injected with 2 x 10 5 GBM1 cells or 8 x 10 4 GBMX1 cells in a volume of 2 µL (containing 30% Matrigel™; BD Biosciences) into the right striatum (2.5 mm from the midline, 2.5 mm anterior from bregma, 3 mm deep). Surgery was performed under general anaesthesia using aseptic techniques. Mice were monitored daily for signs of sickness, pain or weight loss. After the indicated tumor-establishing period, 6 mg/kg KHS101 or vehicle control (5% (v/v) ethanol, 15% (w/v) (2-Hydroxypropyl)-β-cyclo-dextrin) was administered subcutaneously (s.c.) twice daily with bi-weekly alteration of 5 and 3 treatment days per week. Experiments were concluded at indicated endpoints and tissue was subjected to immunohistological and image analysis.
Statistical analysis
For in vitro data, a minimum of 3 independent biological repeats were analyzed using the student's t-test (two tailed, equal variance) and expressed as mean ± SD. One biological repeat comprised a minimum of 3 technical replicates. Approximate normal distribution of data was assumed, however for small sample sizes (n<5), individual data points are identified in the figures. For xenograft tumor analysis, the Mann-Whitney U-test was used (one tailed).
For Kaplan-Meier xenograft tumor analysis, the significance was calculated using the log-rank test. P values of ≤ 0.05 were considered significant (*) and P values of ≤ 0.01 were considered highly significant (**). 
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